相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly
C. Raina MacIntyre et al.
PLOS ONE (2014)
Adult immunization with 13-valent pneumococcal vaccine in Campania region, South Italy An economic evaluation
Giorgio Liguori et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in US Older Adults
Kenneth J. Smith et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2013)
Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model
Roberto Pradas et al.
BMC INFECTIOUS DISEASES (2013)
Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults
Kenneth J. Smith et al.
VACCINE (2013)
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions
Bo-Hyun Cho et al.
VACCINE (2013)
Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy
Sara Boccalini et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Vaccines for preventing pneumococcal infection in adults
Sarah Moberley et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Long-term Comparative Immunogenicity of Protein Conjugate and Free Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease
Mark T. Dransfield et al.
CLINICAL INFECTIOUS DISEASES (2012)
Should 13-Valent Protein-Conjugate Pneumococcal Vaccine Be Used Routinely in Adults?
Daniel M. Musher
CLINICAL INFECTIOUS DISEASES (2012)
Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine
Kenneth J. Smith et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years
Derek Weycker et al.
VACCINE (2012)
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
Mark H. Rozenbaum et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults
Rajeka Lazarus et al.
CLINICAL INFECTIOUS DISEASES (2011)
Serotype replacement in disease after pneumococcal vaccination
Daniel M. Weinberger et al.
LANCET (2011)
Results of a Cohort Model Analysis of the Cost-Effectiveness of Routine Immunization With 13-Valent Pneumococcal Conjugate Vaccine of Those Aged ≥65 Years in the Netherlands
Mark H. Rozenbaum et al.
CLINICAL THERAPEUTICS (2010)
Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine
Tamara Pilishvili et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly
Helen E. Baxendale et al.
VACCINE (2010)
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55-70 Years of Age
Karen M. Miernyk et al.
CLINICAL INFECTIOUS DISEASES (2009)
The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
David Goldblatt et al.
CLINICAL INFECTIOUS DISEASES (2009)
Immunological responses to pneumococcal vaccine in frail older people
I. Ridda et al.
VACCINE (2009)
Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults:: Conjugate vaccine elicits improved antibacterial immune responses and immunological memory
Andres de Roux et al.
CLINICAL INFECTIOUS DISEASES (2008)
Comparison of PubMed, Scopus, Web of Science, and Google Scholar: strengths and weaknesses
Matthew E. Falagas et al.
FASEB JOURNAL (2008)
Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia
Daniel M. Musher et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Immunogenicity of varying dosages of 7-valent pneurnococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Lisa A. Jackson et al.
VACCINE (2007)
Cost-effectiveness of pneurnococcal conjugate vaccine - Evidence from the first 5 years of use in the United States incorporating herd effects
G. Thomas Ray et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine
CA Lexau et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: Role of comorbid conditions and race
JE Sisk et al.
ANNALS OF INTERNAL MEDICINE (2003)
Economic evaluation of vaccination programs: The impact of herd-immunity
M Brisson et al.
MEDICAL DECISION MAKING (2003)
Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly
AM Fry et al.
VACCINE (2002)
分享论文
